Top 10 Companies in the Binders Excipients Market (2026): Market Leaders Powering Global Pharmaceutical Innovation

MARKET INSIGHTS

Global binders excipients market size was valued at USD 1.19 billion in 2024. The market is projected to grow from USD 1.28 billion in 2025 to USD 2.15 billion by 2032, exhibiting a CAGR of 5.8% during the forecast period.

Binders excipients are critical pharmaceutical ingredients used to provide cohesive properties to tablet formulations, ensuring mechanical strength and controlled disintegration. These components include natural polymers like starch and synthetic variants such as polyvinylpyrrolidone (PVP), functioning as adhesive agents in solid dosage manufacturing. Their role extends to maintaining drug stability while optimizing production efficiency.

The market growth is driven by increasing pharmaceutical production volumes, particularly for generic drugs following recent patent expirations. While North America currently dominates due to established pharmaceutical infrastructure, Asia‑Pacific shows fastest growth because of expanding manufacturing capabilities in India and China. Recent industry developments include BASF’s 2024 launch of a novel binder excipient with enhanced compressibility properties, addressing the growing demand for high‑performance formulations.

Binders Excipients Market – View in Detailed Research Report

Top 10 Companies in the Binders Excipients Market (2026)

1. Ashland

   Headquarters: Michigan, USA
   Key Offering: Cellulose derivatives, synthetic polymers, and specialty binders for tablet and capsule formulations.

   Ashland is a global leader in specialty chemical solutions, providing a broad portfolio of binders that deliver high mechanical strength and controlled disintegration. Their advanced formulations support generic and branded pharmaceutical manufacturers across North America, Europe, and Asia.

   Sustainability & Growth Initiatives:

   • Investment in bio‑based cellulose binders to reduce carbon footprint.
   • Collaboration with contract manufacturers to accelerate formulation development.
   • Expansion of R&D in functional excipients for biologics.

2. BASF

   Headquarters: Ludwigshafen, Germany
   Key Offering: Synthetic polymers such as polyvinylpyrrolidone (PVP), polyethylene glycol (PEG), and novel high‑compressibility binders.

   BASF’s 2024 launch of a new binder excipient with enhanced compressibility showcases its commitment to innovation. The company supplies high‑quality binders to pharmaceutical giants, supporting both generic and branded drug development.

   Sustainability & Growth Initiatives:

   • Development of greener polymeric binders with lower VOC emissions.
   • Partnerships with universities to explore nanotechnology‑enabled excipients.
   • Investment in digital manufacturing platforms for binder production.

3. Colorcon

   Headquarters: Ohio, USA
   Key Offering: Film‑coating and binder excipient systems for tablets and capsules.

   Colorcon’s expertise in film‑coating complements its binder portfolio, enabling pharmaceutical companies to achieve superior product quality and shelf life.

   Sustainability & Growth Initiatives:

   • Adoption of low‑water, solvent‑free coating processes.
   • Collaboration with CMOs to streamline formulation workflows.
   • Research into multifunctional binders that also act as disintegrants.

4. Croda International

   Headquarters: Hertfordshire, UK
   Key Offering: Natural and biocompatible excipients, including starch‑based binders and hydroxypropyl‑cellulose.

   Croda’s portfolio supports clean‑label formulations, catering to the growing demand for natural and sustainably sourced excipients.

   Sustainability & Growth Initiatives:

   • Investment in sustainable sourcing of raw materials.
   • Development of biodegradable binders for oral dosage forms.
   • Partnerships with pharma companies focused on green chemistry.

5. EMD Millipore (Merck KGaA)

   Headquarters: Darmstadt, Germany
   Key Offering: Advanced polymeric binders and specialty excipients for pharmaceutical applications.

   EMD Millipore’s global reach and robust R&D enable it to supply high‑performance binders to manufacturers worldwide.

   Sustainability & Growth Initiatives:

   • Development of low‑toxicity binders for sensitive APIs.
   • Investment in digital process analytics for binder quality control.
   • Collaboration with academic institutions on excipient science.

6. Dow Chemical

   Headquarters: Midland, USA
   Key Offering: Polymeric binders, including cellulose derivatives and synthetic polymers.

   Dow Chemical’s extensive portfolio supports a wide range of dosage forms, from tablets to injectable formulations.

   Sustainability & Growth Initiatives:

   • Focus on reducing environmental impact of binder production.
   • R&D into high‑efficiency binders for low‑dose formulations.
   • Strategic partnerships with contract manufacturers.

7. FMC BioPolymer

   Headquarters: Michigan, USA
   Key Offering: Bio‑based polymers and specialty binders for oral and injectable dosage forms.

   FMC BioPolymer’s bio‑based binders cater to the clean‑label market, enhancing drug stability and patient compliance.

   Sustainability & Growth Initiatives:

   • Expansion of bio‑polymer production capacity.
   • Research into multifunctional binders for biologics.
   • Collaboration with pharma companies on sustainability metrics.

8. Fuji Chemical Industry

   Headquarters: Tokyo, Japan
   Key Offering: Starch‑based binders and specialty excipients for tablet and capsule formulations.

   Fuji Chemical Industry serves the Asian market with high‑quality binders that meet stringent regulatory standards.

   Sustainability & Growth Initiatives:

   • Implementation of eco‑friendly manufacturing processes.
   • Partnerships with Japanese pharmaceutical companies for R&D.
   • Investment in advanced granulation technologies.

9. Ingredion

   Headquarters: Michigan, USA
   Key Offering: Starch‑based binders and functional excipients derived from corn and wheat.

   Ingredion’s extensive supply chain supports global pharmaceutical manufacturers seeking cost‑effective binders with consistent performance.

   Sustainability & Growth Initiatives:

   • Focus on sustainable agriculture sourcing of raw materials.
   • Development of low‑energy binders for high‑volume production.
   • Collaboration with contract manufacturers on formulation optimization.

10. Bayer AG

    Headquarters: Leverkusen, Germany
    Key Offering: Cellulose derivatives and specialty binders for pharmaceutical and nutraceutical applications.

    Bayer’s expertise in excipient science supports a broad portfolio of drug products, including generics and specialty formulations.

    Sustainability & Growth Initiatives:

    • Investment in green chemistry for binder production.
    • Partnerships with global pharma companies to develop clean‑label binders.
    • Focus on reducing water usage in binder manufacturing.

Binders Excipients Market – View in Detailed Research Report

Binders Excipients Market – View in Detailed Research Report

Outlook

By 2034, the Global Binders Excipients Market is expected to reach USD 2.5 billion, driven by sustained growth in generic drug manufacturing, expansion of biologics and biosimilars, and the increasing adoption of co‑processed excipients that combine multiple functionalities. The Asia‑Pacific region will continue to lead growth, supported by rising healthcare expenditure and expanding manufacturing capacity in China and India.

Future Trends

• Integration of nanotechnology for enhanced drug release and stability.
• Growth of multifunctional binders that serve as binders, disintegrants, and moisture protectants.
• Increased focus on bio‑based and biodegradable binders to meet clean‑label demands.
• Digitalization of binder production and real‑time quality analytics.
• Strategic collaborations between excipient suppliers and contract manufacturers to accelerate formulation development.